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Agents that interfere with the renin-angiotensin-aldosterone system (RAAS) reduce proteinuria and afford renal protection. Combination of different measures serving maximization of RAAS blockade is thought to improve the antiproteinuric efficacy. We studied in non-diabetic patients with residual proteinuria during previous RAAS blockade the feasibility and efficacy of such a combination strategy by individual antiproteinuric titration. Previous medication was replaced by irbesartan 300 mg combined with a diuretic. Lisinopril was added in increasing doses until a maximal dose of 40 mg/d. Titration stopped when target proteinuria (< 1 g/d) was reached or further dosetitration was not tolerated because of side effects. Residual proteinuria (median (95% CI): 3. The number of patients with adverse events during dose-titration was 5/8 patients: two had cough, two had hyperkalaemia (> 5.5 mmol/L), of whom one had > 50% increase of serum creatinine, and one had dizziness. In conclusion, individual titration for maximal RAAS blockade, entailing dose-titration of an angiotensin-converting enzyme inhibitor on top of a highly dosed angiotensin II type 1 receptor antagonist with diuretic, induces further reduction of residual proteinuria. However, this occurs at expense of adverse events. To further improve renoprotective treatment strategies, it would therefore be important to explore other modes of antiproteinuric intervention in patients with residual proteinuria during RAAS blockade.
roteinuria is nowadays looked upon as an important and independent risk factor for progression of renal disease (1, 2) . Moreover, evidence from large clinical trials has become available, showing that reduction of proteinuria is important for long-term renoprotection (3, 4) . In addition, it has been noted that both residual proteinuria and the amount antiproteinuric response are also predictive for renal outcome in individual patients, indicating that residual proteinuria during therapy is a predictor of the individual renal prognosis (5, 6) . Accordingly, maximum reduction of proteinuria has been advocated as a treatment target for individual renal patients, in addition to control of blood pressure (7) (8) (9) . For optimal renoprotection, therefore, recent data suggest that treatment target for proteinuria should be below 1 g/d, and likely near zero (7, 8) . P Intervention in the renin-angiotensin-system (RAAS) is currently the most effective strategy that combines renoprotection with proteinuria lowering. Roughly, the average antiproteinuric response of RAAS blocking agents is about 50%-both for angiotensin-converting enzyme (ACE) inhibitors and for angiotensin II type 1 (AT1) antagonists (10, 11) . There are several strategies to optimize the response, including dose-titration of the RAAS intervening agents (12) , combining RAAS blockade with low sodium diet or a diuretic (13) , and combining the different RAAS blocking strategies (14) . Indeed, ACE inhibitor plus AT1 antagonist therapy renders more antiproteinuric effect and also more renoprotection (15) . Although each of these measures is widely studied on group level, until now, no individual data of maximal RAAS blockade on proteinuria are available (9) . Moreover, it is unknown whether it is possible, in a prospective fashion, to obtain the target level of proteinuria below 1 g/d by titrating these measures in individual patients. In the present study, our aim was to investigate the antiproteinuric potential of additional up-titration with an ACE inhibitor to maximal tolerated dose against a background of a maximal dosed AT1 antagonist combined with diuretic therapy, in a sodium restricted setting.
METHODS

Patients and protocol
Patients were selected from our renal outpatient clinic. All patients gave informed consent and fulfilled the inclusion criterion of a stable proteinuria > 1 g/d and < 10 g/d while they were still on their previous (non-immune suppressive) antiproteinuric treatment. Only patients with blood pressure < 140/< 90 mm Hg, creatinine clearance ≥ 30 mL/min/1.73 m 2 and age between 18 and 70 years were included. Patients with cardiovascular disease or diabetes mellitus were excluded, as well as frequent users of non-steroidal anti-inflammatory drugs (NSAIDS; > 2 doses/week).
The study was designed as a practice-based clinical trial. Patients were treated according to an individual dose-titration with ACE inhibitors added to a standard treatment of an AT1 antagonist combined with diuretic therapy. Patients were instructed to take the study medication once daily and to adhere to a dietary sodium restriction of 5 to 7 g/d. Our pre-defined treatment goal was to reduce proteinuria below 1 g/d. After selection, eligible patients entered the run-in phase in which previous medication was replaced for the highest recommended daily dose irbesartan 300 mg (16) , combined with the diuretic hydrochlorothiazide 12.5 mg once daily. In patients previously treated with diuretic hydrochlorothiazide or furosemide, the diuretic therapy was continued and solely irbesartan 300 mg was added. Then, patients with proteinuria > 1 g/d and serum potassium concentration < 5.5 mmol/L entered the phase of dose-titration. In this phase, lisinopril was added in increasing daily doses to a maximum of 40 mg. All periods of treatment (run-in and up-titration) lasted at least 6 weeks. The treatment protocol was discontinued when the pre-defined goal of proteinuria < 1 g/d was reached or further dose-titration was not tolerated because of side effects. Expected side effects were defined as hyperkalaemia > 5.5 mmol/L, complaints of cough or dizziness, or serious increase of serum creatinine > 50%.
Clinical and laboratory procedures
Blood pressure was measured at every visit under similar conditions, at one-minute intervals by an automatic device (Dinamap®), with the patient in supine position. After 15 min of measurements, the mean of the last four readings was used for further analysis. Mean arterial pressure (MAP) was calculated as the sum of one-third systolic and two-thirds of the diastolic blood pressure. Urinary protein was determined using the pyrogallol red-molybdate method. At the end of each period, the day previous to every visit, patients collected 24-h urine samples to obtain proteinuria. Serum and urinary electrolytes, uric acid and creatinine were determined using an automated multi-analyzer (SMA-C®; Technicon, Tarrytown, NY, USA).
Data analysis
Results are expressed as median and 95% confidence intervals (95% CI). For each patient, the level of residual proteinuria after treatment with irbesartan combined with hydrochlorothiazide and at the maximal tolerated dose of lisinopril was established. The Wilcoxon signed ranks test was used to test whether paired values from standardized irbesartan 300 mg + diuretic treatment and after treatment with added maximal individual lisinopril dose differed. Differences were considered significant if the p-value was < 0.05. Based on previous data (14) , we calculated that a sample size of n = 6 is needed to detect mean reduction in proteinuria of 40% with expected standard deviation of 28% and with a desired power of 80% and α = 0.05.
RESULTS
Patient characteristics
Twelve non-diabetic proteinuric patients were selected from our outpatient clinic. Four patients, however, did not enter the study protocol because of dizziness (n = 1) or proteinuria < 1 g/d (n = 3) during treatment with irbesartan and diuretic. The remaining 8 patients were included for up-titration with lisinopril and completed the treatment protocol. These patients, all of whom were middle-aged Caucasians, had mild to moderately impaired renal function and had biopsy proven non-diabetic nephropathy with the exception of one patient, in whom it was not possible to perform a biopsy due to anatomical abnormalities (horse shoe kidney) (table 1). During up-titration, three patients achieved the maximal daily dose of lisinopril 40 mg, whereas lisinopril 30 mg, 20 mg, and 10 mg was achieved in 1, 2 and 2 patients, respectively. 
Proteinuria
Off-treatment proteinuria (i.e. without treatment with antihypertensive agents, especially no RAAS intervening agents, or immune suppressive medication) was 5.6 g/d (95% CI: 4.1; 8.4).
Residual proteinuria was 2.9 g/d (1.7; 5.2) on treatment with the combination irbesartan, diuretic, and low sodium diet. Additional dose-titration with lisinopril to the maximal tolerated dose, showed a further proteinuria reduction of 55.6% (16.0; 73.2) to a residual proteinuria of 1.6 (0.8; 3.6) (p = 0.018 vs. irbesartan + diuretic; figure 1 ). Proteinuria-tocreatinine ratio was also significantly reduced (table 2) . Individual up-titration with lisinopril led to further proteinuria reduction in all patients. No relation between the amount of proteinuria reduction (% change) and the dose of lisinopril could be observed (table 3) .
Mean arterial blood pressure was 92 mmHg (95% CI: 77; 111). After up-titration to maximal lisinopril doses, MAP was significantly reduced to 85 mmHg (73; 109) (p = 0.043; figure 1 ). Body weight, serum electrolytes, albumen and lipids were not affected by lisinopril up-titration (table 2) .
With regard to the pre-defined treatment goal, 2 out of 8 patients reached proteinuria of < 1 g/d after the maximal individual dose of lisinopril 10 mg and 40 mg, respectively (table 3) . Six out of 8 did not reach the target proteinuria: 2/6 because they had still residual proteinuria (> 1 g/d) on the highest lisinopril dose, and 4/6 because they experienced side effects that prevented further dose increase of the ACE inhibitors.
Side effects
During up-titration with lisinopril, 5 out of 8 patients experienced adverse symptoms: two patients had hyperkalaemia (> 5.5 mmol/L), two patients complained of cough, and one patient experienced dizziness and had simultaneously > 50% increase of serum creatinine (table 3). One of these five patients also reached the treatment target. Notably, of those patients who experienced adverse effects, none received the maximal additional dose of lisinopril (40 mg QD), whereas in those patients in whom up-titration to the maximal lisinopril dose was possible no side effects were observed. 
DISCUSSION
The results of this study show that maximal RAAS blockade, entailing individual uptitration of the ACE inhibitor lisinopril to maximal tolerated dose in addition to a maximum therapy of the AT1 antagonist irbesartan combined with diuretic and dietary sodium restriction, induces a more than 50% reduction of residual proteinuria in the non-diabetic proteinuric patient. However, this benefit occurs at the expense of a number of adverse events, which clearly limit the feasibility in a considerable proportion of patients to obtain optimal antiproteinuric efficacy with the currently available therapeutic options. Indeed, in only 2 patients, the treatment target of proteinuria < 1 g/d was obtained.
The high incidence of adverse events in our study seems to be at variance with the expectation based on studies in the different renal populations (14, 15, 17, 18) . Clinical studies in both diabetic and non-diabetic renal patients show that dual RAAS blockade led to further proteinuria reduction than with maximal recommended doses of monotherapy (ACE inhibitors or AT1 antagonists) could be obtained, without leading to extra adverse symptoms (14, 17, 18) . Also, in the large trial with 263 non-diabetic patients of Nakao et al., in which the long-term benefit of dual RAAS blockade on hard renal endpoints was demonstrated, the combination therapy of ACE inhibitor and AT1 antagonist was very well tolerated and did not lead to extra side effects compared to monotherapy with trandolapril (15) . To explain the high prevalence of adverse effects in our study, one should take into account that most of the observed adverse symptoms (dizziness, hyperkalaemia, serious impairment of renal function) in our study tend to show a dose-dependent relation, i.e. the further maximization of RAAS blockade is obtained the more adverse effects can be expected. Our treatment schedule was characterized by two distinct measures that contribute to obtain the maximum antiproteinuric effect by a RAAS blockade-based regimen. First, in our treatment schedule, patients were individually titrated for maximal proteinuria reduction with additional lisinopril doses on top of a fixed high dose of irbesartan. Although no data are available on the dose-response of irbesartan for proteinuria reduction, it is expected that the maximal recommended dose for blood pressure reduction also renders the maximal antiproteinuric response, as indicated by most titration studies in proteinuric patients with other AT1 antagonists, as losartan and candesartan, in which a flattening of the dose-response curve is seen after treatment with higher doses (11, 12, 19) . By contrast, increasing the ACE inhibitor dose seems not to show such recline in the dose-response for proteinuria reduction, indicating that higher doses of ACE inhibitor than needed for blood pressure control result in further proteinuria reduction (14) . Therefore, we expect that individual up-titration with increasing doses lisinopril on top of high dosed AT1 antagonist leads to further maximization of blockade of the RAAS for the individual patient. As a consequence, this does not only result in improvement of the antiproteinuric effect, but also to high prevalence of side effects. In contrast, in the study of Nakao et al., the doses of both trandolapril and losartan used for proteinuria reduction were not based on observations in individual patients, but on group level for both trandolapril and losartan (15) . Second, the dual RAAS blockade was given on top of diuretic therapy and dietary sodium restriction. Data from studies in hypertensive patients, but also in proteinuric patients, indicate that both low sodium diet and diuretic therapy can restore the blunted therapy response during RAAS intervening therapy (13) . In our study, patients were instructed to adhere to a sodium-restricted diet which was only moderately successful, as estimated from their 24-h sodium excretion. Moreover, all patients were treated with a diuretic. Since it is known from hypertensive patients that both measures combined act synergistically on the therapy response for blood pressure during ACE inhibitor (20) , it can be anticipated that the combination also leads to further improvement of the antiproteinuric response during dual RAAS blockade. Therefore, individual titration with an ACE inhibitor for the optimal antiproteinuric response on top of a treatment consisting of an AT1 antagonist, a diuretic and dietary low sodium, results in more effective blockade of the RAAS, as indicated by further optimization of proteinuria reduction and blood pressure response. However, as apparent from our data, this strategy has it limits and it may not only be so because of the occurrence of side effects.
We have previously demonstrated that individual antiproteinuric responsiveness to RAAS blockade is an important determinant of the renoprotective efficacy of intervention, and that, despite proven efficacy at group level, the renoprotective effect of RAAS blockade shows a marked between-patient heterogeneity (5) . Therefore, the feasibility of individual titration for proteinuria by optimising the RAAS blockade was explored in this study. However, our present data show that this strategy to overcome individual therapy resistance does not result in abolishment of therapy resistance, which is in accord with other studies, showing that, despite efficacy at group level, poor responders still fail to catch up with good responders (21, 22) .
How could we approach the problem of improving antiproteinuric efficacy for individual patients without enhancing side effects? It would be interesting to explore other non-RAAS intervening modes of therapy directed to maximization of reduction of residual proteinuria. First, different studies demonstrated that intervention in the synthesis of prostaglandins by using non-steroidal-anti-inflammatory drugs (NSAIDs) has antiproteinuric properties with equal effectiveness as ACE inhibitor therapy (23, 24) . Because of the well-known side effects of non-selective NSAIDs, it would be of great interest to explore whether the relative new selective COX-2 inhibitors, of whom lower rates of side effects are reported, share the antiproteinuric properties of NSAIDs, as discussed previously (25) . This issue is currently under investigation by our group. Until now, limited data suggest that addition of COX-2 inhibitors can overcome therapy resistance during ACE inhibitor therapy in membranous glomerulopathy by further reducing residual proteinuria (26) . Second, lipid-lowering drugs, statins in particular, may exert a renoprotective effect, independently from their lipid-lowering effect. In renal patients and in hypertensive patients, long-term treatment with statins is reported to reduce proteinuria (27, 28) . Importantly, statin treatment added to ACE inhibitor and AT1 antagonist therapy was shown to improve proteinuria reduction (28, 29) . Therefore, statins could play role in renal conditions of relative resistance to intervention with RAAS blockade.
In conclusion, individual titration for maximal antiproteinuric efficacy by a RAAS blockade-based regimen results in successful reduction of residual proteinuria. However, this benefit occurs at expense of a number of adverse events. Achievement of proteinuria to lowest levels may probably only be pursued by a multi-drug approach, with intervention in other relevant pathways, such as prostaglandins or lipids. Future studies should address optimal dosing schedules and evaluate the eventual benefit in terms of renal risk.
